Claims for Patent: 9,023,805

Summary for Patent: 9,023,805

Title:	Increasing cancer patient survival time by administration of dithio-containing compounds
Abstract:	The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth \"aggressiveness\" of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.
Inventor(s):	Hausheer; Frederick H. (Boerne, TX)
Assignee:	BioNumerik Pharmaceuticals, Inc. (San Antonio, TX)
Application Number:	12/807,931
Patent Claims:	1. A method for increasing survival time in a patient with cancer who is or will be treated by the administration of one or more chemotherapeutic agents and/or additional related anti-neoplastic agents; wherein said cancer either: (i) overexpresses thioredoxin glutaredoxin and/or (ii) exhibits evidence of thioncdoxin-mediated or glutaredoxin-mediated resistance to the chemotherapy agent or agents used to treat said patient with cancer; wherein said thioredoxin or glutaredoxin overexpression and/or said thioredoxin-mediated or glutaredoxin-mediated treatment resistance is quantitatively determined by use of an analytical methodology selected from the group consisting of fluorescence in situ hybridization (FISH), nucleic acid microarray analysis, immunohistochemistry (IHC), and radioimmunoassay (RIA); wherein said method for increasing survival time in a patient with cancer comprises the administration of a medically-sufficient dose of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient with cancer either prior to, concomitantly with, or subsequent to the administration of a chemotherapy agent or agents whose cytotoxic or cytostatic activity is adversely affected by either: (i) the overexpression of thioredoxin or glutaredoxin and/or (ii) thioredoxin-mediated or glutaredoxin-mediated treatment resistance; and wherein said method for increasing survival time in a patient with cancer may further comprise the administration of a medically-sufficient dose of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies prior to, concomitantly with, or subsequent to the administration of said medically-sufficient dose of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu. 2. The method of claim 1, wherein the cancer is selected from the group consisting of: lung cancer, colorectal cancer, gastric cancer, esophageal cancer, ovarian cancer, cancer of the biliary tract, gallbladder cancer, cervical cancer, breast cancer, endometrial cancer, vaginal cancer, prostate cancer, uterine cancer, hepatic cancer, pancreatic cancer, and adenocarcinoma. 3. A method for increasing survival time in a patient with non-small cell lung carcinoma, who is or will be treated by the administration of one or more chemotherapeutic agents and/or additional related anti-neoplastic agents; wherein said non-small cell lung carcinoma either: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin-mediated or glutaredoxin-mediated resistance to the chemotherapy agent or agents used to treat said patient with non-small cell lung carcinoma; wherein said thioredoxin or glutaredoxin overexpression and/or said thioredoxin-mediated or glutaredoxin-mediated treatment resistance is quantitatively determined by use of an analytical methodology selected from the group consisting of fluorescence in situ hybridization (FISH), nucleic acid microarray analysis, immunohistochemistry (IHC), and radioimmunoassay (RIA); wherein said method for increasin r survival time in a patient with non-small cell lung carcinoma comprises the administration of a medically-sufficient dose of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient with non-small cell lung carcinoma either prior to, concomitantly with, or subsequent to the administration of a chemotherapy agent or agents whose cytotoxic or cytostatic activity is adversely affected by either: (i) the overexpression of thioredoxin or glutaredoxin and/or (ii) thioredoxin-mediated or glutaredoxin-mediated treatment resistance; and wherein said method for increasing survival time in a patient with non-small cell lung carcinoma may further comprise the administration of a medically-sufficient dose of one or more enzymes, proteins, peptides small organic molecules, or polyclonal and/or monoclonal antibodies prior to, concomitantly with, or subsequent to the administration of said medically-sufficient dose of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu. 4. A method for increasing survival time in a patient with adenocarcinoma who is or will be treated by the administration of one or more chemotherapeutic agents and/or additional related anti-neoplastic agents; wherein said adenocarcinoma either: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin-mediated or glutaredoxin-mediated resistance to the chemotherapy agent or agents used to treat said patient with adenocarcinoma; wherein said thioredoxin or glutaredoxin overexpression and/or said thioredoxin-mediated or glutaredoxin-mediated treatment resistance is quantitatively determined by use of an analytical methodology selected from the group consisting of fluorescence in situ hybridization (FISH), nucleic acid microarray analysis, immunohistochemistry (IHC), and radioimmunoassay (RIA); wherein said method for increasing survival time in a patient with adenocarcinoma comprises the administration of a medically-sufficient dose of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient with adenocarcinoma either prior to, concomitantly with, or subsequent to the administration of a chemotherapy agent or agents whose cytotoxic or cytostatic activity is adversely affected by either: (i) the overexpression of thioredoxin or glutaredoxin and/or (ii) thioredoxin-mediated or glutaredoxin-mediated treatment resistance; and wherein said method for increasing survival time in a patient with adenocarcinoma may further comprise the administration of a medically-sufficient dose of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies prior to, concomitantly with, or subsequent to the administration of said medically-sufficient dose of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu. 5. The method of claim 1, claim 3, or claim 4, wherein said chemotherapy agent or agents are selected from the group consisting of: fluropyrimidines; pyrimidine nucleosides; purine nucleosides; anti-folates, platinum agents; anthracyclines/anthracenediones; epipodophyllotoxins; camptothecins; hormones; hormonal complexes; antihormonals; enzymes, proteins, peptides and polyclonal and/or monoclonal antibodies; vinca alkaloids; taxanes; epothilones; antimicrotubule agents; alkylating agents; antimetabolites; topoisomerase inhibitors; aziridine-containing compounds; antivirals; and various other cytotoxic and cytostatic agents. 6. The method of claim 1, claim 3, or claim 4, wherein said chemotherapy agent or agents are selected from the group consisting of: cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, tetraplatin, platinum-DACH, and analogs and derivatives thereof. 7. The method of claim 1, claim 3, or claim 4, wherein said chemotherapy agent or agents are selected from the group consisting of: docetaxel, paclitaxel, polyglutamylated forms of paclitaxel, liposomal paclitaxel, and analogs and derivatives thereof. 8. The method of claim 1, claim 3, or claim 4, wherein the chemotherapy agents are docetaxel and cisplatin. 9. The method of claim 1, claim 3, or claim 4, wherein the chemotherapy agents are paclitaxel and cisplatin. 10. The method of claim 1, claim 3, or claim 4, wherein said enzymes, proteins, peptides, small organic molecules, and polyclonal and/or monoclonal antibodies are selected from the group consisting of asparaginase, cetuximab, erlotinib, bevacizumab, rituximab, gefitinib, trastuzumab, interleukins, interferons, teuprolide, and pegasparaginase. 11. The method of claim 1, claim 3, or claim 4, wherein said monoclonal antibodies are cetuximab or bevacizumab. 12. A method for increasing patient survival time and/or delaying tumor progression in a patient suffering from cancer which is being treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecule, or polyclonal and/or monoclonal antibodies that are also being used to treat said cancer, and wherein said taxane and/or platinum chemotherapy agent or agents, said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 13. The method of claim 12, wherein the cancer is selected from the group consisting of: lung cancer, colorectal cancer, gastric cancer, esophageal cancer, ovarian cancer, cancer of the biliary tract, gallbladder cancer, cervical cancer, breast cancer, endometrial cancer, vaginal cancer, prostate cancer, uterine cancer, hepatic cancer, pancreatic cancer, and adenocarcinoma. 14. A method for increasing patient survival time and/or delaying tumor progression in a patient suffering from non-small cell lung carcinoma which is being treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecule, or polyclonal and/or monoclonal antibodies that are also being used to treat said non-small cell lung carcinoma, and wherein said taxane and/or platinum chemotherapy agent or agents, said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 15. A method for increasing patient survival time and/or delaying tumor progression in a patient suffering from adenocarcinoma which is being treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecule, or polyclonal and/or monoclonal antibodies that are also being used to treat said adenocarcinoma, and wherein said taxane and/or platinum chemotherapy agent or agents, said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are administered to the patient in medically-sufficient dosages. 16. The method of any one of claims 12-15, wherein said increase in patient survival time of said patient treated with a medically-sufficient dose of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu is expected to be at least 30 days longer than the expected survival time if said patient was not treated with a medically-sufficient dose of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu. 17. A method for potentiating the chemotherapeutic effects of a taxane and/or platinum chemotherapy agent or agents used to treat a patient suffering from cancer, wherein said method is comprised of the administration of a 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies that are also being used to treat said cancer, and wherein said 2-mercapto-ethane sulfonate which is conjugate as a disulfide with -Cys-Glu, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 18. The method of claim 17, wherein the cancer is selected from the group consisting of: lung cancer, colorectal cancer, gastric cancer, esophageal cancer, ovarian cancer, cancer of the biliary tract, gallbladder cancer, cervical cancer, breast cancer, endometrial cancer, vaginal cancer, prostate cancer, uterine cancer, hepatic cancer, pancreatic cancer, and adenocarcinoma. 19. A method thr potentiating the chemotherapeutic effects of a taxane and/or platinum chemotherapy agent or agents used to treat a patient suffering from non-small cell ling carcinoma, wherein said method is comprised of the administration of a 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies that are also being used to treat said non-small cell lung carcinoma, and wherein said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 20. A method for potentiating the chemotherapeutic effects of a taxane and/or platinum chemotherapy agent or agents used to treat a patient suffering from adenocarcinoma, wherein said method is comprised of the administration of a 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies that are also being used to treat said adenocarcinoma, and wherein said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 21. A method for promoting the arrest or retardation of tumor progression in a patient suffering from cancer who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies that are also being used to treat said cancer, and wherein said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 22. The method of claim 21, wherein the cancer is selected from the group consisting of: lung cancer, colorectal cancer, gastric cancer, esophageal cancer, ovarian cancer, cancer of the biliary tract, gallbladder cancer, cervical cancer, breast cancer, endometrial cancer, vaginal cancer, prostate cancer, uterine cancer, hepatic cancer, pancreatic cancer, and adenocarcinoma. 23. A method for promoting the arrest or retardation of tumor progression in a patient suffering from non-small cell lung carcinoma who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies that are also being used to treat said non-small cell lung cancer, and wherein said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 24. A method for promoting the arrest or retardation of tumor progression in a patient suffering from adenocarcinoma who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies that are also being used to treat said adenocarcinoma, and wherein said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 25. A method for increasing the survival time while concomitantly maintaining or increasing the quality of life in a patient suffering from cancer who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of a 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies that are also being used to treat said cancer, and wherein said 2 mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 26. The method of claim 25, wherein the cancer is selected from the group consisting of: lung cancer, colorectal cancer, gastric cancer, esophageal cancer, ovarian cancer, cancer of the biliary tract, gallbladder cancer, cervical cancer, breast cancer, endometrial cancer, vaginal cancer, prostate cancer, uterine cancer, hepatic cancer, pancreatic cancer, and adenocarcinoma. 27. A method for increasing the survival time while concomitantly maintaining or increasing the quality of life in a patient suffering from non-small cell lung carcinoma who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies that are also being used to treat said non-small cell lung carcinoma, and wherein said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 28. A method for increasing the survival time while concomitantly maintaining or increasing the quality of life in a patient suffering from adenocarcinoma who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, and wherein the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies that are also being used to treat said adenocarcinoma, and wherein said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 29. A method for increasing the survival time while concomitantly affecting hematological function in a patient suffering from cancer who is treated with a taxane and/or platinum chemotherapy agent or agents, wherein said method is comprised of the administration of 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient, the effect on hematological function is selected from the group consisting of: (i) maintaining or stimulating hematological function, (ii) maintaining or stimulating erythropoietin function or synthesis, mitigating or preventing anemia, and (iv) maintaining or stimulating pluripotent, multipotent, and unipotent normal stem cell function, and the administration of said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu to said patient occurs prior to, concomitantly with, or subsequent to the administration of one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies that are also being used to treat said cancer, and wherein said 2-mercapto-ethane sulfonate which is conjugated as a disulfide with -Cys-Glu, said taxane and/or platinum chemotherapy agent or agents, and said one or more enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are all administered to the patient in medically-sufficient dosages. 30. The method of any one of claims 12-29, wherein said platinum chemotherapy agent or agents are selected from the group consisting of: cisplatin, carboplatin, oxaliplatin, satraplatin, picoplaiin, tetraplatin, platinum-DACH, and analogs and derivatives thereof. 31. The method of any one of claims 12-29, wherein said taxane chemotherapy agent or agents are selected from the group consisting of docetaxel, paclitaxel, polyglutamylated forms of paclitaxel, liposomal paclitaxel, and analogs and derivatives thereof. 32. The method of any one of claims 12-29, wherein the taxane and/or platinum chemotherapy agents are docetaxel and/or cisplatin. 33. The method of any one of claims 12-29, wherein the taxane and/or platinum chemotherapy agents are paclitaxel and/or cisplatin. 34. The method of any one of claims 12-29, wherein said enzymes, proteins, peptides, small organic molecules, or polyclonal and/or monoclonal antibodies are selected from the group consisting of: asparaginase, cetuximab, erlotinib, bevacizumab, rituximab, gefitinib, trastuzumab, interleukins, interferons, leuprolide, and pegasparaginase. 35. The method of any one of claims 12-29, wherein said monoclonal antibodies are cetuximab or bevacizumab.

Details for Patent 9,023,805

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-02-26
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-02-26
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2039-02-26